EUVIMEDEUVIMED entdecken
Systematische ÜbersichtNetzwerk-MetaanalyseOpen Access · CC BY-NC-ND 4.0

Comparative efficacy and safety of treatments for eosinophilic esophagitis: Systematic review and network meta-analysis of randomized controlled trials

Yetiani Roldan, Isabella Silang, Daniel Rayner, Vanessa Wong, Alexandro W L Chu, Nazmul Islam, Michael M Cyr, Ted Xenodemetropoulos, Matthew A Rank, Mary Sherlock, Scott H Sicherer, Hugh A Sampson und 23 weitere

Journal of Allergy and Clinical Immunology · 2026-10

DOI: 10.1016/j.jaci.2026.09.031 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Allergy and Clinical Immunology, 2026-10. Verfasst von Yetiani Roldan und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence, …. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AAAAI, ACAAI, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease characterized by esophageal dysfunction and eosinophilic inflammation. Comparative efficacy and safety of therapies remain uncertain. OBJECTIVE: To compare efficacy and safety of treatments for EoE in children and adults. METHODS: We conducted a systematic review and network meta-analysis (NMA) of randomized controlled trials (RCTs) comparing pharmacologic, dietary, and mechanical interventions. We searched MEDLINE, EMBASE, and CENTRAL to March 17, 2026. Reviewers screened studies, extracted data, and assessed risk of bias. We conducted random-effects NMA; assessed certainty using GRADE. RESULTS: We included 48 RCTs (3,963 participants). High-frequency dupilumab [mean difference (MD) -11.08, 95% confidence interval (CI) -15.14 to -7.03; high certainty] and swallowed topical corticosteroids (STCs) (MD -6.86, 95%CI -9.17 to -4.56; moderate certainty) are likely among the most effective for symptoms. Similarly, high-frequency dupilumab (MD 6.57, 95%CI 3.42 to 9.71; moderate certainty) and STCs (MD 7.20, 95%CI 1.01 to 13.39; moderate certainty) are among the most effective for quality-of-life. Certain biologics and epicutaneous immunotherapy are likely not different from placebo for symptoms (moderate certainty). Multiple interventions reduce peak eosinophil counts (high certainty) and likely do not increase harms versus placebo (moderate or high certainty). Four- and six-food elimination diets (FEDs) may be better than 1FED for symptoms (low certainty), but not other outcomes, with greater burden. CONCLUSIONS: High-frequency dupilumab and STCs are among the most effective therapies across patient-important and inflammatory outcomes. Histologic improvements do not guarantee patient-important outcome improvement. FED benefits are modest and low certainty, and traded off by burdens.

Schlagwörter

Stichwörter der Autor:innen

BiologicsGRADEeosinophilic esophagitisesophageal dilationfood elimination dietsimmunotherapynetwork meta-analysis of randomized controlled trialsproton pump inhibitorsswallowed topical corticosteroidssystematic review

Autor:innen und Institutionen

  • Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada; Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada; Evidence i…
  • Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada; Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada.
  • Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada; Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
  • Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada.
  • Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada; Evidence in Allergy Group, McMaster University, Hamilton, Ontario, Canada.
  • Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.

Förderung

  • AAAAI
  • ACAAI
  • Canadian Institutes of Health Research

Zitieren

APA

Roldan, Y., Silang, I., Rayner, D., Wong, V., Chu, A. W. L., Islam, N., Cyr, M. M., Xenodemetropoulos, T., Rank, M. A., Sherlock, M., Sicherer, S. H., Sampson, H. A., Järvinen, K. M., Bégin, P., Lieberman, J., Chinthrajah, R. S., Mustafa, S. S., Bailey, S. J., Chandra-Puri, A., …, & Chu, D. K. (2026). Comparative efficacy and safety of treatments for eosinophilic esophagitis: Systematic review and network meta-analysis of randomized controlled trials. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2026.09.031

Vancouver

Roldan Y, Silang I, Rayner D, Wong V, Chu AWL, Islam N, et al. Comparative efficacy and safety of treatments for eosinophilic esophagitis: Systematic review and network meta-analysis of randomized controlled trials. Journal of Allergy and Clinical Immunology. 2026. doi:10.1016/j.jaci.2026.09.031

BibTeX
@article{Roldan2026,
  author = {Roldan, Yetiani and Silang, Isabella and Rayner, Daniel and Wong, Vanessa and Chu, Alexandro W L and Islam, Nazmul and Cyr, Michael M and Xenodemetropoulos, Ted and Rank, Matthew A and Sherlock, Mary and Sicherer, Scott H and Sampson, Hugh A and Järvinen, Kirsi M and Bégin, Phillippe and Lieberman, Jay and Chinthrajah, R Sharon and Mustafa, S Shahzad and Bailey, Sally Joo and Chandra-Puri, Anita and Fulkerson, Patricia C and McCabe, Ellen M and Tam, Jonathan S and Groetch, Marion and Crain, Maria and Bernstein, Henry and Cleary, Kelly and Carver, Melanie and Mitchell, Lynda and Gerdts, Jennifer and Brunet, Zachary and Greenhawt, Matthew and Anagnostou, Aikaterini and Shaker, Marcus and Wang, Julie and Chu, Derek K},
  title = {Comparative efficacy and safety of treatments for eosinophilic esophagitis: Systematic review and network meta-analysis of randomized controlled trials},
  journal = {Journal of Allergy and Clinical Immunology},
  year = {2026},
  doi = {10.1016/j.jaci.2026.09.031}
}
Kostenlos starten →